Search Result

Results for "

PPARγ receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) Akt (6) Amyloid-β (2) Androgen Receptor (2) Angiotensin Receptor (3) Antibiotic (2) Apoptosis (10) Aryl Hydrocarbon Receptor (1) Autophagy (3) Bacterial (5) Biochemical Assay Reagents (1) Calcium Channel (1) Cannabinoid Receptor (1) CaSR (1) Cytochrome P450 (2) Drug Intermediate (1) Drug Metabolite (2) Endogenous Metabolite (4) ERK (3) Estrogen Receptor/ERR (1) Ferroptosis (7) Free Fatty Acid Receptor (3) Fungal (1) Glucocorticoid Receptor (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (3) HIV (2) Insecticide (1) Integrin (2) Interleukin Related (2) Isotope-Labeled Compounds (4) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) LXR (4) mTOR (2) NF-κB (1) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) PARP (1) PI3K (2) PKC (2) PPAR (77) Prostaglandin Receptor (6) PTEN (2) Ras (1) Reactive Oxygen Species (ROS) (3) Reference Standards (12) Sirtuin (2) Src (2) STAT (3) Tau Protein (1) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) TRP Channel (1) VD/VDR (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (8) Endocrinology (6) Infection (7) Inflammation/Immunology (20) Metabolic Disease (60) Neurological Disease (10)

By Targets:

ACSL Family (1)

Akt (6)

Amyloid-β (2)

Androgen Receptor (2)

Angiotensin Receptor (3)

Antibiotic (2)

Apoptosis (10)

Aryl Hydrocarbon Receptor (1)

Autophagy (3)

Bacterial (5)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Cannabinoid Receptor (1)

CaSR (1)

Cytochrome P450 (2)

Drug Intermediate (1)

Drug Metabolite (2)

Endogenous Metabolite (4)

ERK (3)

Estrogen Receptor/ERR (1)

Ferroptosis (7)

Free Fatty Acid Receptor (3)

Fungal (1)

Glucocorticoid Receptor (1)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (3)

HIV (2)

Insecticide (1)

Integrin (2)

Interleukin Related (2)

Isotope-Labeled Compounds (4)

Leukotriene Receptor (2)

Ligands for Target Protein for PROTAC (1)

LXR (4)

mTOR (2)

NF-κB (1)

NO Synthase (1)

Nuclear Hormone Receptor 4A/NR4A (1)

PARP (1)

PI3K (2)

PKC (2)

PPAR (77)

Prostaglandin Receptor (6)

PTEN (2)

Ras (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (12)

Sirtuin (2)

Src (2)

STAT (3)

Tau Protein (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

TRP Channel (1)

VD/VDR (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (23)

Cardiovascular Disease (8)

Endocrinology (6)

Infection (7)

Inflammation/Immunology (20)

Metabolic Disease (60)

Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13956

Pioglitazone Maximum Cited Publications 47 Publications Verification U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-50935

Troglitazone 30+ Cited Publications CS-045	PPAR Autophagy Apoptosis Ferroptosis	Metabolic Disease Cancer
Troglitazone is an orally active *PPARγ* agonist, with EC₅₀s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.

HY-15655

GW1929 10+ Cited Publications	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ*, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

HY-19522

Seladelpar 1 Publications Verification MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-19937

Saroglitazar 5+ Cited Publications	PPAR	Metabolic Disease
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-17444

Tesaglitazar	PPAR	Metabolic Disease Cancer
Tesaglitazar is a dual-target PPARα/γ agonist with an EC₅₀ of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .

HY-N0246

Saikosaponin A 5 Publications Verification	LXR Bacterial	Inflammation/Immunology Cancer
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-B0205

Candesartan 5+ Cited Publications CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-N0234

Bavachinin Maximum Cited Publications 8 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-19937A

Saroglitazar magnesium 5+ Cited Publications	PPAR	Metabolic Disease
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-173432

LIBX-A401	ACSL Family Ferroptosis	Neurological Disease Cancer
LIBX-A401 is a selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor with a human IC₅₀ values of 0.38 μM and a K_d of 0.72 μM. LIBX-A401 binds to ACSL4 in an ATP-dependent manner, stabilizes the C-terminal domain, alters the fatty acid gate region, and interacts with residues A329 and Q302 within the fatty acid binding site. LIBX-A401 exhibits anti-ferroptosis properties in cells. LIBX-A401 can be used for the researches of cancer and parkinson's disease .

HY-100348

EPI-001	Androgen Receptor PPAR Apoptosis	Cancer
EPI-001, a selective inhibitor of *Androgen Receptor* (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC₅₀ of ~6 μM. EPI-001 is also a selective modulator of PPARγ**. EPI-001 is active against castration-resistant prostate cancer .

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-15697

TUG-770 3 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC₅₀ of 6 nM for human FFA1. TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research . TUG-770 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-113205

15-keto-Prostaglandin E2 15-keto-PGE2	Endogenous Metabolite Prostaglandin Receptor STAT PPAR Fungal Drug Metabolite	Cardiovascular Disease Infection Endocrinology Cancer
15-keto-Prostaglandin E2 (15-keto-PGE2) is an endogenous PGE₂ metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to the Cys259 residue of STAT3. 15-keto-Prostaglandin E2 binds to and stabilizes EP2 and EP4 receptors. 15-keto-Prostaglandin E2 inhibits the growth and progression of breast cancer cells. 15-keto-Prostaglandin E2 activates *PPAR-γ* and promotes fungal growth. 15-keto-Prostaglandin E2 disrupts glomerular vascularization during zebrafish development and reduces the surface area of the glomerular filtration barrier .

HY-N15574

Saringosterol	LXR Bacterial PPAR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Saringosterol is an orally active steroid found in Sargassum muticum. Saringosterol is a LXR agonist. Saringosterol can lower cholesterol levels and inhibit the mRNA and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C/EBPα). Saringosterol has anti-obesity, anti-atherosclerosis, anti-Mycobacterium tuberculosis and anti-depressant activities .

HY-114263

NXT629 4 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-N1472

Levistolide A 5 Publications Verification	Apoptosis Reactive Oxygen Species (ROS) PPAR GSK-3 Tau Protein Ras TGF-β Receptor	Infection Neurological Disease Inflammation/Immunology
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways .

HY-U00425

PROTAC ERRα ligand 1	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Metabolic Disease Cancer
PROTAC ERRα ligand 1 is a PROTAC target protein ligand. PROTAC ERRα ligand 1 is an orally active ERRα inverse agonist with IC₅₀ values of 0.6 μM for ERRα. PROTAC ERRα ligand 1 shows no significant activity against a panel of other nuclear receptors, including ERα ^c, ERRγ, ERβ, PPARα, PPARγ, PPARδ, and RXRα. PROTAC ERRα ligand 1 can provide enhanced insulin sensitivity in vivo. PROTAC ERRα ligand 1 can be used for metabolic diseases research, such as type 2 diabetes and obesity .

HY-N2110

Phellopterin	Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV	Inflammation/Immunology
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing *PPARγ*. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .

HY-12557

γ-Glutamylvaline γ-Glu-Val	Endogenous Metabolite CaSR Wnt TNF Receptor Interleukin Related PPAR β-catenin	Inflammation/Immunology
γ‑Glutamylvaline (γ-Glu-Val) is a *calcium‑sensing receptor* (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1** and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .

HY-100277

Mifobate 1 Publications Verification SR-202	PPAR	Metabolic Disease
Mifobate (SR-202) is a potent and specific *PPARγ* antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC₅₀=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .

HY-117103

AMG131 INT131	PPAR	Metabolic Disease
AMG131 (INT131) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 binds to *PPARγ* within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 is promising for research of type-2 diabetes mellitus .

HY-128932

Cefminox sodium 1 Publications Verification MT-141	Antibiotic Bacterial PPAR Prostaglandin Receptor PTEN Akt mTOR	Infection Cardiovascular Disease Endocrinology
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and *PPARγ. Cefminox sodium upregulates cAMP* production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .

HY-148418

TUG-499	Free Fatty Acid Receptor	Metabolic Disease
TUG-499 is a selective *free fatty acid receptor* 1 (FFAR1 or GPR40)** (Free Fatty Acid Receptor) agonist with a pEC₅₀ of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-21191

Perfluorobutanesulfonic acid PFBS	Biochemical Assay Reagents PPAR Reactive Oxygen Species (ROS)	Metabolic Disease
Perfluorobutanesulfonic acid (PFBS) is a short-chain perfluoroalkyl substance and the main replacement for perfluorooctanesulfonic acid. Perfluorobutanesulfonic acid induces fat accumulation in human HepG2 hepatoma cells. Perfluorobutanesulfonic acid promotes lipid accumulation by activating PPARγ pathway and triggering oxidative stress, endoplasmic reticulum stress and calcium dyshomeostasis. Perfluorobutanesulfonic acid impairs reproduction and causes developmental disorders in offspring of Caenorhabditis elegans. Perfluorobutanesulfonic acid disrupts pancreatic organogenesis and lipid homeostasis in zebrafish embryos. Perfluorobutanesulfonic acid can be used in environmental toxicology, lipid metabolism and developmental toxicity studies .

HY-112247

SR 16832	PPAR TGF-beta/Smad	Metabolic Disease Inflammation/Immunology
SR 16832 is a dual-site covalent, orthosteric and allosteric PPARγ antagonist. SR 16832 activates the TGF-β signaling pathway and upregulates the expression of Vimentin and Fibronectin (Fibronectin). SR 16832 is toxic to bronchial epithelium. SR 16832 can be used in research related to type 2 diabetes and pulmonary fibrosis .

HY-19522A

Seladelpar sodium 1 Publications Verification MBX-8025 sodium; RWJ-800025 sodium	PPAR	Metabolic Disease Inflammation/Immunology
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .

HY-77278

25-Hydroxytachysterol3	VD/VDR Aryl Hydrocarbon Receptor LXR PPAR	Others
25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .

HY-113827

THPN	Nuclear Hormone Receptor 4A/NR4A	Inflammation/Immunology
THPN is a potent Nur77 agonist. THPN specifically binds the LBD of Nur77 (TR3) but not that of retinoic acid receptor α and PPARγ with a K_d of 270 nM. THPN leads to Nur77 translocation to the mitochondria to induce autophagic cell death in melanoma .

HY-128872

Etrinabdione EHP-101; VCE-004.8	PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific *PPARγ* and CB₂ receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity .

HY-168049

ZLY06	PPAR Akt	Metabolic Disease
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .

HY-168376

9(10)-Nitrooleate 9(10)-Nitrated oleic acid	PPAR ERK Akt NO Synthase	Metabolic Disease Inflammation/Immunology
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates **PPARα, PPARδ and PPARγ** receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .

HY-14831

Arhalofenate 1 Publications Verification MBX 102; JNJ 39659100	PPAR	Metabolic Disease
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor *(PPAR)-γ*, used for the treatment of type 2 diabetes.

HY-101746

GSK376501A	PPAR	Metabolic Disease
GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus .

HY-113631

Amorfrutin B	PPAR	Neurological Disease Metabolic Disease
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with K_i values of 19 nM and EC₅₀ values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .

HY-101676

RG-12525 NID 525	Leukotriene Receptor PPAR Cytochrome P450	Metabolic Disease
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC₅₀ of appr 60 nM and a potent inhibitor of CYP3A4, with a K_i value of 0.5 µM.

HY-14728

Aleglitazar R1439; RO0728804	PPAR	Metabolic Disease
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC₅₀s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .

HY-W339331

Flubendiamide NNI-0001	Insecticide Calcium Channel Reactive Oxygen Species (ROS) Apoptosis	Infection Metabolic Disease
Flubendiamide (NNI-0001) is an orally active phthalic diamide insecticide that acts by targeting insect ryanodine receptors (RyRs), causing insect muscle dysfunction, paralysis and death. Flubendiamide disrupts molting, metamorphosis and reproductive processes, induces oxidative stress by increasing the levels of ROS/RNS, MDA and 8OHdG and decreasing the levels of SOD, CAT and GST, activates the CncC/Maf apoptosis pathway, impairs calcium homeostasis, promotes adipogenesis, increases triglyceride accumulation, and upregulates the expression of regulatory factors for adipocyte differentiation and adipogenesis .

HY-W341997

9-Octadecynoic acid	PPAR	Metabolic Disease
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-50935S

Troglitazone-d4 CS-045-d₄	Isotope-Labeled Compounds PPAR Autophagy Apoptosis Ferroptosis	Cancer
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-13956B

Pioglitazone potassium U 72107 potassium	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) potassium is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .

HY-13956R

Pioglitazone (Standard) U 72107 (Standard)	Reference Standards PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-14728S

Deutaleglitazar Aleglitazar-d₂; R1439-d₂; RO0728804-d₂	PPAR	Others
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and *PPARγ*) .

HY-N0246R

Saikosaponin A (Standard)	Reference Standards LXR Bacterial	Metabolic Disease Inflammation/Immunology
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-B0205R

Candesartan (Standard) CV 11974 (Standard)	Reference Standards Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-19522B

Seladelpar (lysine) 1 Publications Verification MBX-8025 (lysine); RWJ-800025 (lysine)	PPAR	Metabolic Disease
Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .

HY-B0205S

Candesartan-d4 CV-11974-d₄	Angiotensin Receptor	Others
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-19522R

Seladelpar (Standard) MBX-8025 (Standard); RWJ-800025 (Standard)	PPAR Reference Standards	Metabolic Disease
Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-147757

PPARγ/δ modulator 1	PPAR	Metabolic Disease
PPARγ/δ modulator 1 (compound 3e) is a potent PPAR modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with K_i values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC₅₀ of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .

Cat. No.	Product Name	Target	Research Area

HY-12557

γ-Glutamylvaline γ-Glu-Val	Endogenous Metabolite CaSR Wnt TNF Receptor Interleukin Related PPAR β-catenin	Inflammation/Immunology
γ‑Glutamylvaline (γ-Glu-Val) is a *calcium‑sensing receptor* (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1** and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0246

Saikosaponin A 5 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Umbelliferae Plants Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification Cancer	LXR Bacterial
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N0234

Bavachinin Maximum Cited Publications 8 Publications Verification 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-113205

15-keto-Prostaglandin E2 15-keto-PGE2	Structural Classification Ketones, Aldehydes, Acids Marine algae Marine natural products Source Classification	Endogenous Metabolite Prostaglandin Receptor STAT PPAR Fungal Drug Metabolite
15-keto-Prostaglandin E2 (15-keto-PGE2) is an endogenous PGE₂ metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to the Cys259 residue of STAT3. 15-keto-Prostaglandin E2 binds to and stabilizes EP2 and EP4 receptors. 15-keto-Prostaglandin E2 inhibits the growth and progression of breast cancer cells. 15-keto-Prostaglandin E2 activates *PPAR-γ* and promotes fungal growth. 15-keto-Prostaglandin E2 disrupts glomerular vascularization during zebrafish development and reduces the surface area of the glomerular filtration barrier .

HY-N15574

Saringosterol	Structural Classification Marine algae Marine natural products Steroids Source Classification	LXR Bacterial PPAR
Saringosterol is an orally active steroid found in Sargassum muticum. Saringosterol is a LXR agonist. Saringosterol can lower cholesterol levels and inhibit the mRNA and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C/EBPα). Saringosterol has anti-obesity, anti-atherosclerosis, anti-Mycobacterium tuberculosis and anti-depressant activities .

HY-N1472

Levistolide A 5 Publications Verification	Natural Products Classification of Application Fields Dicerothamnus rhinocerotis Umbelliferae Plants Disease Research Fields Source Classification Cancer	Apoptosis Reactive Oxygen Species (ROS) PPAR GSK-3 Tau Protein Ras TGF-β Receptor
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways .

HY-N2110

Phellopterin	Structural Classification Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Inflammation/Immunology Disease Research Fields Source Classification	Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing *PPARγ*. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .

HY-113631

Amorfrutin B	Monophenols Leguminosae Phenols Amorpha fruticosaL. Plants Source Classification	PPAR
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with K_i values of 19 nM and EC₅₀ values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .

HY-W341997

9-Octadecynoic acid	Structural Classification Leguminosae Paramacrolobium coeruleum (Taub.) J.Léonard Ketones, Aldehydes, Acids Plants Source Classification	PPAR
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-13956R

Pioglitazone (Standard) U 72107 (Standard)	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	Reference Standards PPAR Ferroptosis
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N0246R

Saikosaponin A (Standard)	Triterpenes Structural Classification Terpenoids Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification	Reference Standards LXR Bacterial
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N2110R

Phellopterin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Source Classification	Reference Standards Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing *PPARγ*. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.

HY-B1419R

Salicyl alcohol (Standard) 2-Hydroxybenzyl alcohol (Standard); Saligenin (Standard)	Structural Classification Monophenols Microorganisms Phenols Source Classification	Drug Intermediate Reference Standards
Soyasaponin Aa (Standard) is the analytical standard of Soyasaponin Aa. This product is intended for research and analytical applications. Soyasaponin Aa is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ) .

HY-155704

Lyciumamide A	Lycium barbarum L. Phenols Polyphenols Solanaceae Plants Source Classification	PPAR
DPP-IV-IN-5 is isolated from the fruits of Lycium barbarum. DPP-IV-IN-5 exerts moderate agonistic activities for peroxisome proliferator-activated receptor (PPARγ) with EC₅₀ values of 10.09 - 44.26 μM and also presents inhibitory activity on dipeptidyl peptidase-4 (DPPIV) with an IC₅₀ value of 47.13 μM .

HY-N11507

Tibesaikosaponin V TKV	Triterpenes Sonchus asper (L.) Hill Terpenoids Plants Umbelliferae Source Classification	PPAR
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as *peroxisome proliferator-activated receptor* γ** (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Source Classification	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-127003

Neoambrosin	Structural Classification Ambrosia maritima L. Terpenoids Diterpenoids Plants Compositae Source Classification	PPAR TRP Channel
Neoambrosin is a sesquiterpene lactone. Neoambrosin acts as a partial agonist of *PPARγ* and TRPA1 receptors, with no carbonic anhydrase inhibitory activity. Neoambrosin can be used in research on hypoglycemia, analgesia, anti-inflammation and anticancer effects .

HY-N18020

Saurufuran A	Structural Classification Saururaceae Saururus chinensis (Lour.) Baill. Ketones, Aldehydes, Acids Plants Source Classification	Others
Saurufuran A is a PPARγ agonist with an EC₅₀ of 16.7 μM. Saurufuran A is applicable to research related to type 2 diabetes, inflammatory diseases and certain cancers .

Cat. No.	Product Name	Chemical Structure

HY-50935S

Troglitazone-d4
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-14728S

Deutaleglitazar
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and *PPARγ*) .

HY-B0205S

Candesartan-d4
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-107333S

Cinoxate-d3
Cinoxate-d₃ is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with K_i value of 18.0 μM. Cinoxate can be used to study obesity .

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-116028S1

15-deoxy-Δ12,14-Prostaglandin D2-d4

15-Deoxy-Δ12,14-Prostaglandin D2-d₄ (15-Deoxy-Δ12,14-PGD2-d₄) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks